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Abstract: Obesity is a major public health problem, which has a strong genetic component that
interplays with environmental factors. Several genes are known to be implicated in the regulation
of body weight. The identification of alleles that can be associated with obesity is a key element
to control this pandemic. On the basis of a Portuguese population, 65 obesity-related genes are
sequenced using Next-Generation Sequencing (NGS) in 72 individuals with obesity, in order to
identify variants associated with monogenic obesity and potential risk factors. A total of 429 variants
are identified, 129 of which had already been associated with the phenotype. Comparing our results
with the European and Global frequencies, from 1000 Genomes project, 23 potential risk variants are
identified. Six new variants are discovered in heterozygous carriers: four missense (genes ALMS1-
NM_015120.4:c.5552C>T; SORCS1-NM_001013031.2:c.1072A>G and NM_001013031.2: c.2491A>C;
TMEM67-NM_153704.5:c.158A>G) and two synonymous (genes BBS1-NM_024649.4:c.1437C>T;
TMEM67-NM_153704.5:c.2583T>C). Functional studies should be performed to validate these new
findings and evaluate their penetrance and pathogenicity. Regardless of no cases of monogenic
obesity being identified, this kind of investigational study is important when we are still trying to
understand the aetiology and pathophysiology of obesity. This will allow the identification of rare
variants associated with obesity and the study of their prevalence in specific populational groups.
Keywords: obesity; monogenic obesity; next-generation sequencing (NGS); obese women
1. Introduction
Obesity is a major public health problem. The World Health Organization estimated
that in 2016 more than 650 million adults (13% of the world’s population) would be obese
and 1.9 billion (39% of the world’s population) would be overweight [1]. In Portugal, it
was estimated that in 2017, 22.3% of the population was obese [2].
Obesity is a complex disease influenced by the interaction of genetic and environmen-
tal factors [3] and a major risk factor for the development of other conditions, such as type
2 diabetes mellitus, hypertension, cardiovascular diseases and even certain types of cancer.
The presence of these severe co-morbidities is responsible for the increased risk of mortality
in these individuals [4,5].
Obesity can also be one of the phenotypic characteristics in syndromic diseases, such as
the Prader-Willi syndrome, Bardet-Biedl syndrome or Albright’s hereditary osteodystrophy,
but this only accounts for a small percentage of obesity cases.
Moreover, cases of non-syndromic monogenic obesity are also very rare, accounting
for less than 5% of diagnoses in Europe [6]. Non-syndromic monogenic obesity may have
a dominant or recessive inheritance, resulting from a pathogenic mutation in genes with an
essential role in maintaining energy homeostasis by participating in the leptin-melanocortin
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signalling pathway. These include the LEP, LEPR, MC4R, POMC and PCSK1 genes. A
mutation with loss of function in one of these genes in homozygous carriers will cause dis-
ruption in this signalling pathway, resulting in monogenic obesity [3,4,6]. Approximately
140 variants in these genes associated with non-syndromic monogenic obesity are docu-
mented in the ClinVar (https://www.ncbi.nlm.nih.gov/ClinVar (accessed on 3 January
2020)) and Ensembl (https://www.ensembl.org (accessed on 3 January 2020)) databases.
Most often, obesity has a polygenic and multifactorial origin. Polygenic, since it
results from the presence of several common variants. When these variants are isolated,
they have no or little metabolic effects, but when they are together, they increase the
susceptibility to gain weight [7]. Multifactorial, since it is related not only to predisposing
genetic factors, but also to the “obesogenic” environment, associated with a sedentary
lifestyle (imbalance between intake and energy expenditure) and social and cultural factors.
These non-genetic factors, such as nutrition and physical activity, also seem to have an
impact on the modulation of gene activity, due to changes in the epigenetic signatures [3].
Therefore, the identification of variants associated with obesity is extremely relevant
for differential diagnosis, for treatment selection in these patients and for prenatal diagnosis
in families where a known variant was found.
Despite all the research studies already conducted, the aetiology of obesity is still far
from being fully understood. The development of further studies, in order to identify new
genes and variants involved in the regulation of body weight and obesity, and the study of
their prevalence in a specific population, will allow us to move towards a future focused
on the patient, with more effective prevention, follow-up and personalised treatment.
With this in mind, the primary aim of this research is to find new genetic variants
linked to obesity and assess its prevalence in a Portuguese population.
2. Materials and Methods
We considered 65 genes (exons and exon-intron junctions), previously identified as
risk factors for obesity development, which were sequenced by NGS, in a Portuguese group
of obese/overweight individuals.
2.1. Patient Selection
The study sample consisted of 72 individuals (55 females, aged between 21 and
67 years and with a body mass index (BMI) between 26.9 and 68.0 kg/m2, followed up
at the Multidisciplinary Obesity Department of the Centro Hospitalar Universitário de
Lisboa Central (Curry Cabral). The collection of the samples occurred after the individual
signature of an informed consent. The protocol was approved by the Ethical Committee of
ESTeSL (CE-ESTESL-No.41-2018).
2.2. Laboratory Analysis
Oral epithelium cells were collected with swab and DNA was extracted with Ex-
tractMe kit® from BLIRT SA. The success of the extraction was evaluated by a fluorimetric
method using the QuBit® equipment and the Qubit dsDNA high-sensitivity assay, from
ThermoFisher Scientific (target-selective dyes bound to DNA and emit fluorescence). For
all samples, some after 2 elutions, it was possible to reach the minimum concentration
required for subsequent sequencing of the panel of 65 genes by NGS.
After obtaining the desired DNA concentrations, the libraries were prepared with
TruSight One kit® from Illumina, Inc. (San Diego, CA, USA) respecting the manufacturer’s
instructions. Sequencing was performed on the NextSeq550 equipment from Illumina, Inc
using the NextSeq 500/550 High Output Kit v2 (150 cycles).
The gene panel used includes genes associated with monogenic obesity and the
leptin-melanocortin signalling pathway (LEP, LEPR, PCSK1, POMC and MC4R) [3], genes
associated with insulin signalling pathway (IRS1, IRS2, IRS4 and SORCS1) [8–10], genes as-
sociated with lipid metabolism (ADRB1 and ADRB3, PRKAR1, PTEN and SPG11), [11–14]
other genes associated with appetite regulation (BDNF, NTRK2, LRP2, MCHR1 and
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SLC6A14 [13–17] genes associated with syndromic obesity (ALMS1 and BBS family),
among other genes previously associated with obesity (Table 1) [3,17–19].
Table 1. Gene panel (genes previously associated with obesity).
ADRB1 BBS8/TTC8 CPE LRP2 NTRK2 SLC6A14
ADRB2 BBS9 FTO MAGEL2 PAX6 SNRPN
ADRB3 BBS10 G6PC MC3R PCK1 SORCS1
ALMS1 BBS11/TRIM32 GNAS MC4R PCSK1 SPG11
BBS1 BBS12 IGF2 MCHR1 PHF6 TBX3
BBS2 BBS13/MKS1 IGF2R MKRN3 POMC THRB
BBS3/ARL6 BBS14/CEP290 IRS1 NDN PPARG TMEM67
BBS4 BBS15/WDPCP IRS2 NEGR1 PRKAR1A UCP1
BBS5 BBS17/LZTFL1 IRS4 NPY PTEN UCP2
BBS6/MKKS BDNF LEP NPY1R SH2B1 UCP3
BBS7 CCDC28B LEPR NPY2R SIM1
2.3. Data Analysis
The analysis of the obtained data began with the pre-processing of the sequences,
and the variant calling, in the Enrichment and BWA Enrichment applications of Illumina,
Inc. For the variant annotation, the software Illumina Variant Studio 3.0 was used. Only
variants detected in both applications (Enrichment and BWA Enrichment of Illumina,
Inc.) and passing the PASS filter of Illumina Variant Studio 3.0, were considered for the
continuation of the study. Variants outside exons and exon-intron regions (up to 12 bases)
were also excluded.
To check the quality of readings, coverage and read depth, Software IGV-Integrative
Genomics Viewer was used.
For the analysis of the identified variants, prediction of their impact and clinical
relevance, we used ClinVar (NCBI), a public database, where associations between human
genetic variants and phenotypes, scientifically based, are reported, and PolyPhen-2, a
software available online, which predicts the possible impact of amino acid substitutions
on the stability and function of human proteins. In this software, SNPs are functionally
annotated, coding SNPs are mapped to gene transcripts, protein sequence annotations and
structural attributes are extracted and conservation profiles are developed. The probability
of the missense mutation being harmful is then calculated using a combination of these
properties. In Polyphen, we can find two variant classifiers, HumDIV and HumVAR. Only
predictions from HumDIV will be presented in this study, since is considered preferential
for rare alleles [20]. We also resort to the Human Splicing Finder to evaluate the impact on
splicing, of intron, missense and synonymous variants located in splicing regions (1–3 bases
of the exon, 1–8 bases of the intron).
To identify risk variants associated with obesity, the frequencies of the variants
identified in this study were compared with European and Global frequencies in the
1000 Genomes project (https://www.internationalgenome.org (accessed on 6 January
2020) and, when not reported, in TopMed (https://www.nhlbiwgs.org/ (accessed on
6 January 2020). To be considered a risk allele, the difference between the frequency in the
studied sample and the European and Global reference frequency had to be equal to or
greater than 1.41% (corresponding to the proportion of two alleles in the calculated sample
frequency−2/(2 × 71)).
3. Results
Of the 72 samples analysed, a coverage smaller than 80% was obtained in eight
samples. After applying the PASS filter Illumina Variant Studio, variants were detected
in all samples, except for one. The use of a non-invasive method for sample collection
(oral epithelium cells collected with swabs) was probably the reason for the low coverage
detected in these samples. To perform the technique, it was necessary to obtain a DNA
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concentration higher than 5 ng/µL per sample, which for some samples was only possible
after a second extraction and elution. Effectively, the efficiency of DNA recovery and
extraction from swabs is usually, regardless of the material, less than 50% [21].
Globally, 429 different variants were identified in 63 of the 65 genes under study:
423 snv’s (single nucleotide variant), 1 mnv (multiple nucleotide variant), 2 insertions
and 3 deletions. In absolute numbers, 4348 variants were detected: 4318 snv’s, 6 mnv’s,
21 insertions and 3 deletions.
No variants were detected in PHF6 and PTEN genes. After verifying the mean
coverage value of these sequences, we could rule out the suspicion of inefficacy of the
enrichment probes.
3.1. Variant Consequences
Analysing the 429 different variants identified (Table 2), missense variants were the
most frequent, counting 48.25%, followed by the synonymous variants with 41.49%. Ac-
cording to the 1000 Genomes Project, 52.09% of these variants have a European prevalence
of less than 1%.
Table 2. Variants classified by consequence.
Variant Consequences Number of Variants
Number of Variants with a European
Prevalence <1% According to the
1000 Genomes Project
Missense variant 207 122
Synonymous variant 178 75
Intron variant 38 23
3′ prime UTR variant 3 0
Nonsense variant 2 2
Frameshift variant 1 1
Inframe deletion 1 1
Inframe insertion 1 0
According to PolyPhen HumDIV, of the 207 missense variants identified, 125 are pre-
dicted to be benign, 35 are possibly damaging and 44 probably damaging. Three variants
have unknown impact. In absolute numbers, 1701 missense variants were detected,
1435 benign, 117 possibly damaging and 145 probably damaging.
Table 3 describes the clinical associations that may be related to obesity, the number of
variants identified and the number of samples where these variants were detected.
Table 3. Clinical association of the identified variants potentially associated with obesity.





Obesity Susceptibility 3 44 35
Obesity 5 40 34
Monogenic obesity 13 228 66
Syndromic obesity 94 671 71
Childhood obesity 2 13 13
Type 2 Diabetes Mellitus 5 45 32
Monogenic Diabetes 12 26 20
Insulin resistance 2 23 20
Influence on BMI 3 35 23
Leptin deficiency or disfunction 2 3 3
Leptin receptor deficiency 5 138 59
Metabolic syndrome
susceptibility 2 77 50
Thyroid hormone resistance 3 27 27
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A total of 129 variants are potentially associated with obesity, according to ClinVar
and the consulted bibliography, some of which have more than a clinical association. Of
these variants, seven are classified as a risk factor, one is classified as probably pathogenic
and three as pathogenic (Table 4).
Table 4. Clinical association of the identified variants potentially associated with obesity.
Gene dbSNP ID Ho He ClinVar Disease PolyPhenHumDIV
ADRB2 rs1042713 23 23 Risk factor Metabolic syndrome Benign
ADRB2 rs1042714 31 20 Risk factor Metabolic syndrome, obesity Benign
ADRB3 rs4994 0 10 Risk factor Obesity Benign
IRS1 rs1801278 1 11 Risk factor Insulin resistance Possibly damaging
IRS2 rs1805097 2 20 Risk factor Diabetes Mellitus -
PCSK1 rs6232 0 5 Risk factor Obesity Benign
POMC rs28932472 0 2 Risk factor Early-onset obesity Probably damaging
BBS2 rs773417074 0 1 Prob pathogenic Bardet-Biedl syndrome -
MKKS rs74315394 0 1 Pathogenic Mckusick Kaufman syndrome Probably damaging
SPG11 rs199588440 0 1 Pathogenic Spastic paraplegia 11
UCP3 rs2229707 0 1 Pathogenic Severe obesity, T2 Diabetes Benign
Ho—homozygotic; He—Heterozygotic.
3.2. Variant Incidence
Of the 65 genes studied and considering the 64 samples with coverage greater than
80.00%, in three genes, variants were found in 100% of the samples: ALMS1, LRP2 and
NEGR1 (Figure 1), followed by the BBS4 and PCK1 genes, with variants in 98.44% of
the samples.
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In the 64 samples, we found variants in an average of 26.69 genes and an average of
66.2 variants per sample.
3.3. Identification of Potential Risk Alleles
The identified potential risk alleles associated with obesity are described in Table 5.
Table 5. Potential risk alleles associated with obesity.
Gene dbSNP ID Variant Freq (%) Eur Freq (%) Gl Freq (%)
ADRB2 rs1800888 c.491C>T p.Thr164Ile 3.52 1.79 0.40
ALMS1 rs41291187 c.1868A>G p.His623Arg 3.52 2.09 0.70
BBS9 rs11773504 c.1363G>A p.Ala455Thr 21.83 19.58 17.13
IGF2R rs76130099 c.5701G>A p.Val1901Ile 2.11 0.60 0.42
IGF2R rs22 7367 c.6995+6C>T 10.56 4.87 7.09
I S1 rs2234931 c.702G>A c.702G>A(p. =) 11. 7 8.55 5.29
LRP2 rs147058423 c.3110G>A p.Arg1037Lys 1.41 0.1 0.02
LRP2 rs189273089 c.9592G>A p.Glu3198Lys 1.41 0.00 0.04
LRP2 rs41268685 c.13250G>A p.Gly4417Asp 2.82 1.19 0.58
LRP2 rs183867145 c.894A>G c.894A>G(p. =) 1.41 0.00 0.02
LRP2 rs34104660 c.402C>A c.402C>A(p. =) 9.86 8.15 4.75
LRP2 rs33954745 c.2376T>C c.2376T>C(p. =) 9.86 8.45 7.63
NPY1R rs5578 c.1121A>C p.Lys374Thr 2.82 0.69 0.30
NTRK2 rs2289657 c.1848C>A c.1848C>A(p. =) 8.45 4.37 5.81
POMC rs80326661 c.641A>G p.Glu214Gly 2.11 0.69 0.14
SPG11 rs80338869 c.7023C>T c.7023C>T(p. =) 7.04 3.18 1.18
SPG11 rs79708848 c.1698T>G p.Asp566Glu 2.82 1.39 0.52
TMEM67 rs117195541 c.2397T>C c.2397T>C(p. =) 2.82 1.39 0.84
Freq—Frequency in the studied sample; Eur Freq—European frequency according to 1000 Genome Project; Gl Freq—Global Frequency
according to the 1000 Genome Project.
Although they did n t fully meet the criteria defin d previously, variants rs183867145,
rs147058423 and rs1 9273089 (found in LRP2 gene) were also considered as potential
risk ri ts associated with obesity. Eff ctively, according to the 1000 Ge omes Project,
variant rs183867145 w s only identified n one American heterozygous individual, variant
rs147058423 in a European heter zygous individual and variant rs189273089 in two het-
erozygous carriers, one American and one African. The thre v riants ere detec ed each
in two indivi ua s in our sample.
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In five variants, the frequency of the minor allele in the sample was lower than the
European and Global frequencies, according to 1000 Genomes project (Table 6). These
findings suggest that the c.724-8G allele of the BBS1 gene, c.196G of the BDNF gene,
c.2512A of the BBS14/CEP290 gene, c.745C of the IGF2R gene and c.84T of the SLC6A14
gene constitute potential risk alleles for obesity.
Table 6. Variants in which the frequency of the minor allele is lower than European/global frequencies.
Gene dbSNP ID Variant Freq (%) Eur Freq (%) Gl Freq (%)
BBS1 rs10896125 c.724-8G>C 17.90 23.96 24.26
BBS14/CEP290 rs11104738 c.2512A>G p.Lys838Glu 2.86 4.87 9.70
BDNF rs6265 c.196G>A p.Val66Met 8.73 19.68 20.13
IGF2R rs8191754 c.754C>G p.Leu252Val 12.14 14.81 16.03
SLC6A14 rs12720074 c.84T>A c.84T>A(p. =) 0.82 9.66 5.40
Freq—Frequency in the studied sample; Eur Freq.—European frequency according to 1000 Genome Project; Gl Freq.—Global Frequency
according to the 1000 Genome Project.
3.4. New Variants
In the variant analysis, six new variants were detected, all in heterozygous carriers.
These variants, localised in genes ALMS1, BBS1, SORCS1 and TMEM67 were not referenced
in the consulted databases. The variant c.5552C>T, in the ALMS1 gene, results in a missense
variant, where a Proline is replaced by a Leucine in the amino acid 1851. This variant has
a PolyPhen prediction of possibly damaging. The variant c.1437C>T, in the BBS1 gene,
results in a synonymous variant. The variant c.1072A>G, in the SORCS1 gene, results in a
missense variant, where an Arginine is replaced by a Glycine in the amino acid 358. This
variant has a PolyPhen prediction of possibly damaging. The variant c.2491A>C, in the
SORCS1 gene, results in a missense variant, where a Threonine is replaced by a Proline in
the amino acid 831. This variant has a PolyPhen prediction of probably damaging. The
variant c.158A>G, in gene TMEM67, results in a missense variant, where a Glutamine is
replaced by an Arginine in the amino acid 53. This variant has a PolyPhen prediction of
benign. The variant c.2583T>C, in gene TMEM67, results in a synonymous variant.
To validate these results, functional studies should be performed.
4. Discussion
In the 72 individuals studied, no cases of monogenic obesity were recognised. In all
samples, several variants were identified that constitute risk factors associated with obesity
(between 3 and 12 variants per individual), which may influence the development of this
phenotype in these individuals.
Of all the variants identified in this study, only five (Table 7), found in heterozygous
carriers, have a ClinVar classification of pathogenic or probably pathogenic.
Table 7. Pathogenic or probably pathogenic variants identified.
Gene dbSNP ID Variant ClinVar Disease PolyPhen HumDIV
BBS2 rs773417074 c.627_628delTTp.Cys210SerfsTer20
Probably
Pathogenic Bardet-Biedl syndrome -
LRP2 rs138269726 c.6160G>A p.Asp2054Asn Pathogenic Donnai Barrow syndrome Probably damaging
MKKS rs74315394 c.724G>T p.Ala242Ser Pathogenic Mckusick Kaufmansyndrome Probably damaging
SPG11 rs199588440 c.1951C>T p.Arg651Ter Pathogenic Spastic paraplegia 11 -
UCP3 rs2229707 c.304G>Ap.Val102Ile Pathogenic Severe obesity, T2Diabetes Benign
The four syndromes referenced in Table 6 have autosomal recessive transmission, and,
with the exception of the Donnai-Barrow Syndrome, obesity may be part of the pheno-
type [14,22,23]. The variant rs2229707 is described as associated with severe obesity and
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was detected in a study conducted by Argyropoulos et al., in an obese woman in heterozy-
gosity (39 years), in three obese descendants in homozygosity (11, 14 and 20 years—BMI is
higher in older individuals) and in a non-obese descendant (9 years) in heterozygosity [24].
The information from this study and the other consulted bibliography is not enough to
define whether this mutation may be associated with monogenic obesity and whether it
has autosomal dominant or recessive heredity. In one of our samples, this variant was
detected along with another possibly damaging variant in the UCP3 gene (rs8179180), both
in heterozygosity. This sample belongs to an obese woman, whose father and mother, three
siblings and two children are obese. It would be interesting to carry out the same study,
sequencing the 65 genes, to all family members (including non-obese family members,
who are not included in the available family history). Thus, we could test the penetrance
and evaluate the clinical significance, and association with obesity, of these two variants
identified in the UCP3 gene.
Limitations
One of the limitations of this study was the use of a sample collected by a non-invasive
method (samples of oral epithelium cells collected by swab). This was probably the reason
for the low coverage detected in some samples and the lack of results in one of the samples.
The chosen NGS technique also failed to detect chromosomal structural changes such as
massive deletions, insertions, inversions, or duplications, as well as epigenetic changes
that may have occurred [9,25]. The lack of detailed clinical and family history of the
individuals under study, namely associated co-morbidities, cases of childhood obesity or
the identification of non-obese family members, and the non-sequencing of samples of
relatives (ascending and descending), hindered the interpretation of the found variants,
although it would help in the establishment of correlations between alleles and phenotypes.
The variant frequency analysis was also hampered by the lack of a control group and the
use of a database, the 1000 Genomes Project, in which obesity was not an exclusion criterion
and there was no representation from Portugal [26].
5. Final Considerations
This study aimed to identify new genetic variants associated with obesity and to
determine its prevalence in the Portuguese population. The development of similar studies
may allow in the future to easily identify individuals at high risk of developing obesity in
order to define more effective preventive strategies. In that sense, it will allow personalised
medicine to be applied to the obesity field.
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